Basophil Activation Test is a Relevant Biomarker of the Outcome of Rapid Desensitization in Platinum Compounds-Allergy
Carregando...
Citações na Scopus
71
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
Citação
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, v.5, n.3, p.728-736, 2017
Resumo
BACKGROUND: Rapid drug desensitization (RDD) has become a cornerstone in the management of immediate drug hypersensitivity reactions (DHRs) to chemotherapeutic agents. Because of the inherent risk of anaphylaxis during RDD, biomarkers to predict patients at risk of developing such severe reactions are needed. The basophil activation test (BAT) has been used in DHRs as a diagnostic tool. OBJECTIVE: We evaluated basophil CD63 and CD203c expression (BAT) as a biomarker to assess the safety and effectiveness of RDD in platinum compounds-allergic patients. METHODS: Patients allergic to platinum compounds (n = 15) undergoing RDD were assessed through clinical history, skin testing, serum tryptase levels, and BAT. BAT was performed immediately before RDD, assessing CD203c and CD63 expression on basophils. BAT was also performed in 6 patients tolerant to platinum compounds and in 6 healthy volunteers. RESULTS: BAT was positive to CD203c or CD63 in 11 out of 15 patients allergic to platinum compounds (73%), with increased expression of CD203c and CD63 in 11 (73%) and 6 (40%) patients, respectively. Increased CD63 expression tended to be associated with more severe initial reactions. All controls had negative test results. Reactions during RDD were associated with BAT positivity and increased tryptase levels. Only 1 of 4 patients with negative BAT had a mild reaction during RDD. BAT remained positive in multiple sequential RDD. CONCLUSIONS: BAT identified patients allergic to platinum compounds with an increased risk of reactions during desensitization and higher CD63 expression was observed in severe reactions. Multiple RDDs to platinum compounds did not induce persistent hyporesponsiveness on basophils. BAT is a potential biomarker for RDD. (C) 2016 American Academy of Allergy, Asthma & Immunology
Palavras-chave
Anaphylaxis, Basophil activation test, Drug allergy, Platinum compounds, Rapid drug desensitization
Referências
- Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754
- Andrews NL, 2009, IMMUNITY, V31, P469, DOI 10.1016/j.immuni.2009.06.026
- Balzer L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108619
- Bidad K, 2014, CYTOM PART B-CLIN CY, V86, P183, DOI 10.1002/cyto.b.21148
- Brennan PJ, 2009, J ALLERGY CLIN IMMUN, V124, P1259, DOI 10.1016/j.jaci.2009.09.009
- Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029
- Caiado J, 2013, J ALLER CL IMM-PRACT, V1, P494, DOI 10.1016/j.jaip.2013.06.002
- Castells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044
- Cernadas JR, 2010, ALLERGY, V65, P1357, DOI 10.1111/j.1398-9995.2010.02441.x
- Cox L, 2010, J ALLERGY CLIN IMMUN, V125, P569, DOI 10.1016/j.jaci.2009.10.060
- de Weck AL, 2008, INT ARCH ALLERGY IMM, V146, P177, DOI 10.1159/000115885
- Ford LS, 2013, J ALLERGY CLIN IMMUN, V131, P180, DOI 10.1016/j.jaci.2012.06.003
- Gadducci A, 2008, INT J GYNECOL CANCER, V18, P615, DOI 10.1111/j.1525-1438.2007.01063.x
- Giavina-Bianchi P, 2013, ALLERGY, V68, P1482, DOI 10.1111/all.12228
- Giavina-Bianchi P, 2015, CURR TREAT OPTIONS A, V2, P268
- Iwamoto T, 2014, CANCER SCI, V105, P1472, DOI 10.1111/cas.12538
- Iwamoto T, 2012, BIOL PHARM BULL, V35, P1487
- Jakobsen A, 1997, J CLIN ONCOL, V15, P193
- Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591
- Kim BH, 2009, ONCOLOGY-BASEL, V76, P231, DOI 10.1159/000205263
- Li Q, 2014, GYNECOL ONCOL, V135, P90, DOI 10.1016/j.ygyno.2014.07.104
- MacGlashan DW, 2013, J ALLERGY CLIN IMMUN, V132, P777, DOI 10.1016/j.jaci.2013.06.038
- Macy E, 2014, J ALLERGY CLIN IMMUN, V133, P790, DOI 10.1016/j.jaci.2013.09.021
- Madrigal-Burgaleta R, 2013, ALLERGY, V68, P853, DOI 10.1111/all.12105
- Makrilia Nektaria, 2010, Metal-Based Drugs, P207084, DOI 10.1155/2010/207084
- Markman M, 1999, J CLIN ONCOL, V17, P1141
- Mezzano V, 2014, BIODRUGS, V28, P133, DOI 10.1007/s40259-013-0066-x
- Moon DH, 2013, BRIT J CANCER, V109, P1072, DOI 10.1038/bjc.2013.389
- Mori Y, 2010, ONCOLOGY-BASEL, V79, P136, DOI 10.1159/000320613
- Novak N, 2012, J ALLERGY CLIN IMMUN, V130, P1153, DOI 10.1016/j.jaci.2012.04.039
- Ocmant A, 2007, J IMMUNOL METHODS, V320, P40, DOI 10.1016/j.jim.2006.12.002
- Oka T, 2013, J ALLERGY CLIN IMMUN, V132, P922, DOI 10.1016/j.jaci.2013.05.004
- Parel M, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-1
- Rubio A, 2011, ALLERGY, V66, P92, DOI 10.1111/j.1398-9995.2010.02432.x
- Sancho-Serra MD, 2011, EUR J IMMUNOL, V41, P1004, DOI 10.1002/eji.201040810
- Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012
- Sanz ML, 2002, CLIN EXP ALLERGY, V32, P277, DOI 10.1046/j.1365-2222.2002.01305.x
- Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010
- Seki K, 2011, INT J MED SCI, V8, P210
- Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]
- Siu SWK, 2006, ANN ONCOL, V17, P259, DOI 10.1093/annonc/mdj042
- Song Woo-Jung, 2013, Asia Pac Allergy, V3, P266, DOI 10.5415/apallergy.2013.3.4.266
- SORENSEN BT, 1993, CANCER CHEMOTH PHARM, V31, P324, DOI 10.1007/BF00685679
- Sturm EM, 2010, CYTOM PART B-CLIN CY, V78B, P308, DOI 10.1002/cyto.b.20526
- van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014
- Viardot-Helmer A, 2008, HAUTARZT, V59, P883, DOI 10.1007/s00105-008-1653-5
- Wong JT, 2014, J ALLER CL IMM-PRACT, V2, P40, DOI 10.1016/j.jaip.2013.08.011
- 2010, ANN ALLERG ASTHMA IM, V105, P259, DOI 10.1016/J.ANAI.2010.08.002